Type 2 diabetes drug associated with increased cardiovascular risk

A study has shown that type 2 diabetes drug rosiglitazone is associated with an increased cardiovascular risk, especially for heart failure events. The BMJ study is the most comprehensive evaluation of the cardiovascular risk of rosiglitazone ever done and has used individual patient level data (IPD) made available by makers GlaxoSmithKline. Rosiglitazone belongs to a class of drugs called thiazolidinediones. It helps control blood sugar levels in patients with type 2 diabetes, but it can also increase the risk of serious heart problems. This has led to suspension of the drug in Europe and previous restrictions on its use in the US. Since 2007, studies have